Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 148

1.

Activation of liver X receptor up-regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms.

Bilotta MT, Abruzzese MP, Molfetta R, Scarno G, Fionda C, Zingoni A, Soriani A, Garofalo T, Petrucci MT, Ricciardi MR, Paolini R, Santoni A, Cippitelli M.

FASEB J. 2019 May 24:fj201900319R. doi: 10.1096/fj.201900319R. [Epub ahead of print]

PMID:
31125275
2.

The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors.

Abruzzese MP, Bilotta MT, Fionda C, Zingoni A, Soriani A, Petrucci MT, Ricciardi MR, Molfetta R, Paolini R, Santoni A, Cippitelli M.

Cell Death Dis. 2019 Apr 11;10(4):324. doi: 10.1038/s41419-019-1562-9.

3.

Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice.

Broccoli A, Casadei B, Chiappella A, Visco C, Tani M, Cascavilla N, Conconi A, Balzarotti M, Cox MC, Marino D, Goldaniga MC, Marasca R, Tecchio C, Patti C, Musuraca G, Devizzi L, Monaco F, Romano A, Fama A, Zancanella M, Paolini R, Rigacci L, Castellino C, Gaudio F, Argnani L, Zinzani PL.

Oncologist. 2019 Apr 2. pii: theoncologist.2018-0603. doi: 10.1634/theoncologist.2018-0603. [Epub ahead of print]

PMID:
30940746
4.

The Ubiquitin-proteasome pathway regulates Nectin2/CD112 expression and impairs NK cell recognition and killing.

Molfetta R, Milito ND, Zitti B, Lecce M, Fionda C, Cippitelli M, Santoni A, Paolini R.

Eur J Immunol. 2019 Jun;49(6):873-883. doi: 10.1002/eji.201847848. Epub 2019 Mar 27.

PMID:
30888046
5.

Time series analysis of ambient air-temperature during the period 1970-2016 over Sydney, Australia.

Livada I, Synnefa A, Haddad S, Paolini R, Garshasbi S, Ulpiani G, Fiorito F, Vassilakopoulou K, Osmond P, Santamouris M.

Sci Total Environ. 2019 Jan 15;648:1627-1638. doi: 10.1016/j.scitotenv.2018.08.144. Epub 2018 Aug 11.

PMID:
30340306
6.

Translating the anti-myeloma activity of Natural Killer cells into clinical application.

Fionda C, Stabile H, Molfetta R, Soriani A, Bernardini G, Zingoni A, Gismondi A, Paolini R, Cippitelli M, Santoni A.

Cancer Treat Rev. 2018 Nov;70:255-264. doi: 10.1016/j.ctrv.2018.10.005. Epub 2018 Oct 10. Review.

PMID:
30326421
7.

Rituximab, bendamustine and cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma.

Tisi MC, Paolini R, Piazza F, Ravelli E, Tecchio C, Sartori R, Famengo B, D'Amore ESG, Carli G, Perbellini O, Di Bona E, Ruggeri M, Visco C.

Am J Hematol. 2018 Dec;93(12):E386-E389. doi: 10.1002/ajh.25278. Epub 2018 Oct 9. No abstract available.

PMID:
30184246
8.

Abnormal regulation of BCR signalling by c-Cbl in chronic lymphocytic leukaemia.

Martini V, Frezzato F, Severin F, Raggi F, Trimarco V, Martinello L, Molfetta R, Visentin A, Facco M, Semenzato G, Paolini R, Trentin L.

Oncotarget. 2018 Aug 14;9(63):32219-32231. doi: 10.18632/oncotarget.25951. eCollection 2018 Aug 14.

9.

Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma.

Broccoli A, Casadei B, Morigi A, Sottotetti F, Gotti M, Spina M, Volpetti S, Ferrero S, Spina F, Pisani F, Merli M, Visco C, Paolini R, Zilioli VR, Baldini L, Di Renzo N, Tosi P, Cascavilla N, Molica S, Ilariucci F, Rigolin GM, D'Alò F, Vanazzi A, Santambrogio E, Marasca R, Mastrullo L, Castellino C, Desabbata G, Scortechini I, Trentin L, Morello L, Argnani L, Zinzani PL.

Oncotarget. 2018 May 4;9(34):23443-23450. doi: 10.18632/oncotarget.25215. eCollection 2018 May 4.

10.

NKG2D and Its Ligands: "One for All, All for One".

Zingoni A, Molfetta R, Fionda C, Soriani A, Paolini R, Cippitelli M, Cerboni C, Santoni A.

Front Immunol. 2018 Mar 12;9:476. doi: 10.3389/fimmu.2018.00476. eCollection 2018. Review.

11.

Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells.

Zitti B, Molfetta R, Fionda C, Quatrini L, Stabile H, Lecce M, de Turris V, Ricciardi MR, Petrucci MT, Cippitelli M, Gismondi A, Santoni A, Paolini R.

Sci Rep. 2017 Sep 5;7(1):10445. doi: 10.1038/s41598-017-10403-0.

12.

Regulation of NKG2D-Dependent NK Cell Functions: The Yin and the Yang of Receptor Endocytosis.

Molfetta R, Quatrini L, Santoni A, Paolini R.

Int J Mol Sci. 2017 Aug 2;18(8). pii: E1677. doi: 10.3390/ijms18081677. Review.

13.

Targeted therapy in severe asthma today: focus on immunoglobulin E.

Pelaia G, Canonica GW, Matucci A, Paolini R, Triggiani M, Paggiaro P.

Drug Des Devel Ther. 2017 Jun 29;11:1979-1987. doi: 10.2147/DDDT.S130743. eCollection 2017. Review.

14.

Epstein-Barr Virus-Positive Mucocutaneous Ulcer Mimicking Rectal Carcinoma at 18F-FDG PET/CT.

Maffione AM, Rampin L, Paolini R, Rodella E, Lisato LC, Ballotta MR, Pavanato G, Montesi G, Colletti PM, Rubello D.

Clin Nucl Med. 2017 Aug;42(8):645-646. doi: 10.1097/RLU.0000000000001725.

PMID:
28590301
15.

3D Microfluidic model for evaluating immunotherapy efficacy by tracking dendritic cell behaviour toward tumor cells.

Parlato S, De Ninno A, Molfetta R, Toschi E, Salerno D, Mencattini A, Romagnoli G, Fragale A, Roccazzello L, Buoncervello M, Canini I, Bentivegna E, Falchi M, Bertani FR, Gerardino A, Martinelli E, Natale C, Paolini R, Businaro L, Gabriele L.

Sci Rep. 2017 Apr 24;7(1):1093. doi: 10.1038/s41598-017-01013-x.

16.

Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production.

Capuano C, Pighi C, Molfetta R, Paolini R, Battella S, Palmieri G, Giannini G, Belardinilli F, Santoni A, Galandrini R.

Oncoimmunology. 2017 Feb 10;6(3):e1290037. doi: 10.1080/2162402X.2017.1290037. eCollection 2017.

17.

Genotoxic stress modulates the release of exosomes from multiple myeloma cells capable of activating NK cell cytokine production: Role of HSP70/TLR2/NF-kB axis.

Vulpis E, Cecere F, Molfetta R, Soriani A, Fionda C, Peruzzi G, Caracciolo G, Palchetti S, Masuelli L, Simonelli L, D'Oro U, Abruzzese MP, Petrucci MT, Ricciardi MR, Paolini R, Cippitelli M, Santoni A, Zingoni A.

Oncoimmunology. 2017 Jan 13;6(3):e1279372. doi: 10.1080/2162402X.2017.1279372. eCollection 2017.

18.

Plasma matrix metalloprotease 9 correlates with blood lymphocytosis, leukemic cell invasiveness, and prognosis in B-cell chronic lymphocytic leukemia.

Gusella M, Bolzonella C, Paolini R, Rodella E, Bertolaso L, Scipioni C, Bellini S, Cuneo A, Pasini F, Ramazzina E.

Tumour Biol. 2017 Feb;39(2):1010428317694325. doi: 10.1177/1010428317694325.

PMID:
28240053
19.

p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells.

Soriani A, Borrelli C, Ricci B, Molfetta R, Zingoni A, Fionda C, Carnevale S, Abruzzese MP, Petrucci MT, Ricciardi MR, La Regina G, Di Cesare E, Lavia P, Silvestri R, Paolini R, Cippitelli M, Santoni A.

Oncoimmunology. 2016 Dec 2;6(1):e1264564. doi: 10.1080/2162402X.2016.1264564. eCollection 2017.

20.

Antiplatelet therapy in patients with glucose-6-phosphate dehydrogenases deficiency after percutaneous coronary intervention: A reappraisal for clinical and interventional cardiologists.

Zuin M, Rigatelli G, Carraro M, Galasso MP, Dell'Avvocata F, Paolini R, Zuliani G, Roncon L.

Cardiovasc Revasc Med. 2017 Apr - May;18(3):226-229. doi: 10.1016/j.carrev.2016.11.011. Epub 2016 Nov 28. Review.

PMID:
27914991
21.

Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.

Abruzzese MP, Bilotta MT, Fionda C, Zingoni A, Soriani A, Vulpis E, Borrelli C, Zitti B, Petrucci MT, Ricciardi MR, Molfetta R, Paolini R, Santoni A, Cippitelli M.

J Hematol Oncol. 2016 Dec 1;9(1):134.

22.

Regulation of NKG2D Expression and Signaling by Endocytosis.

Molfetta R, Quatrini L, Zitti B, Capuano C, Galandrini R, Santoni A, Paolini R.

Trends Immunol. 2016 Nov;37(11):790-802. doi: 10.1016/j.it.2016.08.015. Epub 2016 Sep 22. Review.

PMID:
27667711
23.

[Central venous catheter-related right atrial thrombosis in a patient with Hodgkin's lymphoma].

Lanza D, Paolini R, Rodella E, Danesi TH, Cresce G, Salvador L, Roncon L.

G Ital Cardiol (Rome). 2016 May;17(5):388-90. doi: 10.1714/2252.24270. Italian.

PMID:
27310913
24.

Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities.

Baldazzi C, Luatti S, Zuffa E, Papayannidis C, Ottaviani E, Marzocchi G, Ameli G, Bardi MA, Bonaldi L, Paolini R, Gurrieri C, Rigolin GM, Cuneo A, Martinelli G, Cavo M, Testoni N.

Genes Chromosomes Cancer. 2016 Apr;55(4):375-88. doi: 10.1002/gcc.22341. Epub 2016 Jan 27.

PMID:
26815134
25.

Ubiquitin-dependent endocytosis of NKG2D-DAP10 receptor complexes activates signaling and functions in human NK cells.

Quatrini L, Molfetta R, Zitti B, Peruzzi G, Fionda C, Capuano C, Galandrini R, Cippitelli M, Santoni A, Paolini R.

Sci Signal. 2015 Oct 27;8(400):ra108. doi: 10.1126/scisignal.aab2724.

PMID:
26508790
26.

The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma.

Fionda C, Abruzzese MP, Zingoni A, Cecere F, Vulpis E, Peruzzi G, Soriani A, Molfetta R, Paolini R, Ricciardi MR, Petrucci MT, Santoni A, Cippitelli M.

Oncotarget. 2015 Sep 15;6(27):23609-30.

27.

Anti-CD20 Therapy Acts via FcγRIIIA to Diminish Responsiveness of Human Natural Killer Cells.

Capuano C, Romanelli M, Pighi C, Cimino G, Rago A, Molfetta R, Paolini R, Santoni A, Galandrini R.

Cancer Res. 2015 Oct 1;75(19):4097-108. doi: 10.1158/0008-5472.CAN-15-0781. Epub 2015 Jul 30.

28.

Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells.

Zingoni A, Cecere F, Vulpis E, Fionda C, Molfetta R, Soriani A, Petrucci MT, Ricciardi MR, Fuerst D, Amendola MG, Mytilineos J, Cerboni C, Paolini R, Cippitelli M, Santoni A.

J Immunol. 2015 Jul 15;195(2):736-48. doi: 10.4049/jimmunol.1402643. Epub 2015 Jun 12.

29.

Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation.

Fionda C, Abruzzese MP, Zingoni A, Soriani A, Ricci B, Molfetta R, Paolini R, Santoni A, Cippitelli M.

BMC Cancer. 2015 Jan 22;15:17. doi: 10.1186/s12885-015-1023-5.

30.

Response criteria for malignant lymphoma.

Maffione AM, Paolini R, Rodella E, Ambrosio C, Rampin L, Lisato LC, Ballotta M, Pavanato G, Rubello D.

Nucl Med Commun. 2015 Apr;36(4):398-405. doi: 10.1097/MNM.0000000000000263.

PMID:
25603273
31.

Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia.

Moreno C, Montillo M, Panayiotidis P, Dimou M, Bloor A, Dupuis J, Schuh A, Norin S, Geisler C, Hillmen P, Doubek M, Trněný M, Obrtlikova P, Laurenti L, Stilgenbauer S, Smolej L, Ghia P, Cymbalista F, Jaeger U, Stamatopoulos K, Stavroyianni N, Carrington P, Zouabi H, Leblond V, Gomez-Garcia JC, Rubio M, Marasca R, Musuraca G, Rigacci L, Farina L, Paolini R, Pospisilova S, Kimby E, Bradley C, Montserrat E.

Haematologica. 2015 Apr;100(4):511-6. doi: 10.3324/haematol.2014.118158. Epub 2015 Jan 16.

32.

NK cells and interferons.

Paolini R, Bernardini G, Molfetta R, Santoni A.

Cytokine Growth Factor Rev. 2015 Apr;26(2):113-20. doi: 10.1016/j.cytogfr.2014.11.003. Epub 2014 Nov 13. Review.

PMID:
25443799
33.

Regulation of fc receptor endocytic trafficking by ubiquitination.

Molfetta R, Quatrini L, Gasparrini F, Zitti B, Santoni A, Paolini R.

Front Immunol. 2014 Sep 18;5:449. doi: 10.3389/fimmu.2014.00449. eCollection 2014. Review.

34.

c-Cbl regulates MICA- but not ULBP2-induced NKG2D down-modulation in human NK cells.

Molfetta R, Quatrini L, Capuano C, Gasparrini F, Zitti B, Zingoni A, Galandrini R, Santoni A, Paolini R.

Eur J Immunol. 2014 Sep;44(9):2761-70. doi: 10.1002/eji.201444512. Epub 2014 Jun 17.

35.

Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia.

Perbellini O, Falisi E, Giaretta I, Boscaro E, Novella E, Facco M, Fortuna S, Finotto S, Amati E, Maniscalco F, Montaldi A, Alghisi A, Aprili F, Bonaldi L, Paolini R, Scupoli MT, Trentin L, Ambrosetti A, Semenzato G, Pizzolo G, Rodeghiero F, Visco C.

Haematologica. 2014 May;99(5):881-7. doi: 10.3324/haematol.2013.096362. Epub 2014 Jan 10.

36.

Oxantel disrupts polymicrobial biofilm development of periodontal pathogens.

Dashper S, O'Brien-Simpson N, Liu SW, Paolini R, Mitchell H, Walsh K, D'Cruze T, Hoffmann B, Catmull D, Zhu Y, Reynolds E.

Antimicrob Agents Chemother. 2014;58(1):378-85. doi: 10.1128/AAC.01375-13. Epub 2013 Oct 28.

37.

Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice.

Zaja F, Mian M, Volpetti S, Visco C, Sissa C, Nichele I, Castelli M, Ambrosetti A, Puglisi S, Fanin R, Cortelazzo S, Pizzolo G, Trentin L, Rodeghiero F, Paolini R, Vivaldi P, Sancetta R, Isola M, Semenzato G.

Am J Hematol. 2013 Nov;88(11):955-60. doi: 10.1002/ajh.23546. Epub 2013 Sep 9.

38.

Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques.

Said MA, Johnson HL, Nonyane BA, Deloria-Knoll M, O'Brien KL; AGEDD Adult Pneumococcal Burden Study Team, Andreo F, Beovic B, Blanco S, Boersma WG, Boulware DR, Butler JC, Carratalà J, Chang FY, Charles PG, Diaz AA, Domínguez J, Ehara N, Endeman H, Falcó V, Falguera M, Fukushima K, Garcia-Vidal C, Genne D, Guchev IA, Gutierrez F, Hernes SS, Hoepelman AI, Hohenthal U, Johansson N, Kolek V, Kozlov RS, Lauderdale TL, Mareković I, Masiá M, Matta MA, Miró Ò, Murdoch DR, Nuermberger E, Paolini R, Perelló R, Snijders D, Plečko V, Sordé R, Strålin K, van der Eerden MM, Vila-Corcoles A, Watt JP.

PLoS One. 2013;8(4):e60273. doi: 10.1371/journal.pone.0060273. Epub 2013 Apr 2. Review.

39.

The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia.

Visco C, Finotto S, Pomponi F, Sartori R, Laveder F, Trentin L, Paolini R, Di Bona E, Ruggeri M, Rodeghiero F.

Am J Hematol. 2013 Apr;88(4):289-93. doi: 10.1002/ajh.23391. Epub 2013 Feb 28.

40.

Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation.

Visco C, Finotto S, Zambello R, Paolini R, Menin A, Zanotti R, Zaja F, Semenzato G, Pizzolo G, D'Amore ES, Rodeghiero F.

J Clin Oncol. 2013 Apr 10;31(11):1442-9. doi: 10.1200/JCO.2012.45.9842. Epub 2013 Feb 11.

PMID:
23401442
41.

Syk-dependent regulation of Hrs phosphorylation and ubiquitination upon FcεRI engagement: impact on Hrs membrane/cytosol localization.

Gasparrini F, Molfetta R, Quatrini L, Frati L, Santoni A, Paolini R.

Eur J Immunol. 2012 Oct;42(10):2744-53. doi: 10.1002/eji.201142278. Epub 2012 Jul 25.

42.

Boron nitride nanotubes as templates for half-metal nanowires.

Batista RJ, de Oliveira AB, Pereira NR, Paolini RS, Manhabosco TM.

J Phys Condens Matter. 2012 Apr 25;24(16):165501. doi: 10.1088/0953-8984/24/16/165501. Epub 2012 Mar 26.

PMID:
22447845
43.

PIP2-dependent regulation of Munc13-4 endocytic recycling: impact on the cytolytic secretory pathway.

Capuano C, Paolini R, Molfetta R, Frati L, Santoni A, Galandrini R.

Blood. 2012 Mar 8;119(10):2252-62. doi: 10.1182/blood-2010-12-324160. Epub 2012 Jan 23.

44.

Cbl family proteins: balancing FcεRI-mediated mast cell and basophil activation.

Gasparrini F, Molfetta R, Santoni A, Paolini R.

Int Arch Allergy Immunol. 2011;156(1):16-26. doi: 10.1159/000322236. Epub 2011 Mar 29. Review.

PMID:
21447956
45.

Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination.

Ferreri AJ, Licata G, Foppoli M, Corazzelli G, Zucca E, Stelitano C, Zaja F, Fava S, Paolini R, Franzin A, Politi LS, Ponzoni M, Reni M.

Oncologist. 2011;16(3):336-41. doi: 10.1634/theoncologist.2010-0361. Epub 2011 Feb 23.

46.

Porphyromonas gingivalis cysteine proteinase inhibition by kappa-casein peptides.

Toh EC, Dashper SG, Huq NL, Attard TJ, O'Brien-Simpson NM, Chen YY, Cross KJ, Stanton DP, Paolini RA, Reynolds EC.

Antimicrob Agents Chemother. 2011 Mar;55(3):1155-61. doi: 10.1128/AAC.00466-10. Epub 2010 Dec 20.

47.

Ubiquitination and endocytosis of the high affinity receptor for IgE.

Molfetta R, Gasparrini F, Santoni A, Paolini R.

Mol Immunol. 2010 Sep;47(15):2427-34. doi: 10.1016/j.molimm.2010.06.003. Epub 2010 Jul 16. Review.

PMID:
20638130
48.

From methylene blue (methylthionine chloride) to Al-Ghorab procedure: the therapy of priapism (our experience).

Passavanti G, Bragaglia A, Paolini R.

Arch Ital Urol Androl. 2009 Dec;81(4):242-4.

PMID:
20608149
49.

Autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia is associated with IgVH status.

Visco C, Novella E, Peotta E, Paolini R, Giaretta I, Rodeghiero F.

Haematologica. 2010 Jul;95(7):1230-2. doi: 10.3324/haematol.2010.022079. Epub 2010 Apr 21. No abstract available.

50.

Attenuation of PI3K/Akt-mediated tumorigenic signals through PTEN activation by DNA vaccine-induced anti-ErbB2 antibodies.

Porzia A, Lanzardo S, Citti A, Cavallo F, Forni G, Santoni A, Galandrini R, Paolini R.

J Immunol. 2010 Apr 15;184(8):4170-7. doi: 10.4049/jimmunol.0903375. Epub 2010 Mar 10.

Supplemental Content

Loading ...
Support Center